

# National Stock Exchange of India

## Circular

<b>DEPARTMENT: LISTING</b>	
<b>Download Ref. No.: NSE/CML/66254</b>	<b>Date: January 22, 2025</b>
<b>Circular Ref. No.: 0132/2025</b>	

To All Members,

**Sub: Listing of Equity Shares of Onesource Specialty Pharma Limited pursuant to the Scheme of Arrangement**

In pursuance of Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the list of securities further admitted to dealings on the National Stock Exchange (Capital Market segment) with effect from January 24, 2025 and the designated security codes thereof shall be as specified in Annexure.

In pursuance of Regulation 2.5.5 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the respective lot sizes in respect of securities above shall be as specified in Annexure. For the purpose of trading on the system, the security shall be identified only by its designated codes and trading in such securities shall be in such lot sizes as specified in Annexure.

Members are requested to note that the above security will be part of pre-open session as per SEBI circular no. CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012.

This circular shall be effective from January 24, 2025

**For and on behalf of  
National Stock Exchange of India Limited**

**Snehal Mariappa  
Manager**

### Annexure

#### 1. Onesource Specialty Pharma Limited

Symbol	ONESOURCE
Name of the Company	Onesource Specialty Pharma Limited
Series	BE - Trade for Trade *
Security Description	Equity shares of Re.1/- each allotted pursuant to Scheme of Arrangement
ISIN	INE013P01021
Face Value	Re. 1/-
Paid-up Value	Re. 1/-
No. of securities	114436021
Distinctive number range	Annexure I
Market lot	1
Pari Passu	Yes
Lock-in details	Annexure I

\* Note: Currently the securities shall be available for trading in Series 'BE' and subsequently be shifted to Series 'EQ' as per SEBI circular no. SEBI/CIR/ISD/1/2010 dated September 2, 2010

<p><b>Registered Address:</b>  <b>Onesource Specialty Pharma Limited</b>  201, Devavrata, Sector 17,  Vashi, Sanpada,  Thane - 400703  <b>Email:</b> <a href="mailto:cs@onesourcecdmo.com">cs@onesourcecdmo.com</a></p> <p><b>Corporate Address:</b>  <b>Onesource Specialty Pharma Limited</b>  Star 1 Opposite IIM Bangalore,  Bilekahalli, Bannerghatta Road,  South Bangalore, Bengaluru -560 076</p> <p><b>Contact Person – Ms. Allada Trisha</b>  <b>Website:</b> <a href="http://www.onesourcecdmo.com">www.onesourcecdmo.com</a>  <b>Email:</b> <a href="mailto:cs@onesourcecdmo.com">cs@onesourcecdmo.com</a></p>	<p><b>Address of the Registrar and Share Transfer Agent:</b>  <b>Integrated Registry Management Services Private Limited</b>  2<sup>nd</sup> Floor, “Kences Towers”, No. 1 Ramakrishna Street, North Usman Road, T Nagar, Chennai – 600 017  Tel: 044 – 2814 0801/ 2814 0803</p> <p><b>Contact Person:</b> Mr. S Yuvaraj  <b>Website:</b> <a href="http://www.integratedindia.in">www.integratedindia.in</a>  <b>Email:</b> <a href="mailto:einward@integratedindia.in">einward@integratedindia.in</a></p>
--	--

The brief particulars of the Scheme of Arrangement are as mentioned below:

- a) The National Company Law Tribunal, Mumbai Bench, vide its order dated November 14, 2024 has approved the Scheme of Arrangement among Strides Pharma Science Limited (“Transferor Company 1 or Demerged Company 1”) and Steriscience Specialities Private Limited (“Transferor Company 2 or Demerged Company 2”) and Onesource Speciality Pharma Limited (formally known as Stelis Biopharma Limited) (“Transferee Company or Resulting Company”) and their respective shareholders and creditors.

- i. Demerger of Identified Contract Development and Manufacturing (CDMO) Business and Soft Gelatin Business (Demerged Undertaking 1) of Strides Pharma Science Limited (SPSL) into Onesource Specialty Pharma Limited (Formerly Known as Stelis Biopharma Limited), an unlisted Associate Company of SPSL, whereby upon coming into effect of the scheme and in consideration of;

"1 (One) Fully Paid-up Equity Share of Rs.1/- each of Onesource Specialty Pharma Limited (Formerly Known as Stelis Biopharma Limited) for every 2 (Two) Fully Paid-Up Equity Share of Rs. 10/- each held in Strides Pharma Science Limited"

- ii. Demerger of Identified Contract Development and Manufacturing (CDMO) Business (Demerged Undertaking 2) of Steriscience Specialties Private Limited (SSPL), an unlisted promoter group company, into Onesource Specialty Pharma Limited (Formerly Known as Stelis Biopharma Limited), an unlisted Associate Company of SPSL, whereby upon coming into effect of the scheme and in consideration of;

"1515 (One Thousand Five Hundred and Fifteen) Fully Paid-up Equity Share of Rs.1/- each of Onesource Specialty Pharma Ltd. (Formerly Known as Stelis Biopharma Limited) for every 1 (One) Fully Paid-Up Equity Share of Rs. 10/- each held in Steriscience Specialties Private Ltd. (SSPL)".

Prior to the Scheme, the paid-up Equity Capital of Onesource Specialty Pharma Ltd. (Formerly Known as Stelis Biopharma Limited) was Rs. 4,78,24,419/- consisting of 4,78,24,419 equity shares of Face Value of Re. 1/- each and out of that 11089320 equity shares held by Strides Pharma Science Ltd. (SPSL) are cancelled.

The issued, subscribed and paid-up equity capital of Onesource Specialty Pharma Ltd. (Formerly Known as Stelis Biopharma Limited), post Arrangement is Rs. 11,44,36,021/- consisting of 11,44,36,021 equity shares of face Value of Re. 1/- each fully paid.

b) Appointed Date: 01-Apr-2024

c) Effective date: 27-Nov-2024

d) Date of Allotment: 10-Dec-2024

**Annexure I**

<b>No. of Equity Shares Fully Paid-up</b>	<b>Distinctive Nos.</b>		<b>Lock-in upto Date</b>
	<b>From</b>	<b>To</b>	
9378312	1	9378312	20-Jan-2028
27356787	9378313	36735099*	20-Jan-2026
773755	47824420*	48598174	20-Jun-2025
76927167	48598175	125525341	Free
<b>114436021</b>	<b>Total</b>		

\*Note: 11089320 shares were cancelled due to scheme of Arrangement